These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27451997)

  • 1. DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents.
    Tjokroprawiro A; Murtiwi S; Tjandrawinata RR
    J Complement Integr Med; 2016 Dec; 13(4):413-420. PubMed ID: 27451997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa.
    Manaf A; Tjandrawinata RR; Malinda D
    Drug Des Devel Ther; 2016; 10():1279-89. PubMed ID: 27099473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Safety of DLBS3233, A Combined Bioactive Fraction of
    Hestiantoro A; Permadi W; Tjandrawinata RR; Wiweko B; Ritonga MA; Ferrina AI; Sumapraja K; Muharam R; Djuwantono T
    Int J Fertil Steril; 2024 Jul; 18(Suppl 1):35-47. PubMed ID: 39033369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect and Safety Assessment of Metformin and DLBS3233 (A Bioactive Fraction of
    Hidayat ST; Mulyantoro I; Damas S; Tjandrawinata RR
    Int J Womens Health; 2023; 15():971-985. PubMed ID: 37424700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
    Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.
    Rosenstock J; Franco D; Korpachev V; Shumel B; Ma Y; Baughman R; Amin N; McGill JB;
    Diabetes Care; 2015 Dec; 38(12):2274-81. PubMed ID: 26253730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinnamomum zeylanicum (Ceylon cinnamon) as a potential pharmaceutical agent for type-2 diabetes mellitus: study protocol for a randomized controlled trial.
    Ranasinghe P; Galappaththy P; Constantine GR; Jayawardena R; Weeratunga HD; Premakumara S; Katulanda P
    Trials; 2017 Sep; 18(1):446. PubMed ID: 28962661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.